Lambert-Eaton Myasthenic Syndrome (LEMS)

es gibt schon etwas was verabreicht wird bei LEMSyndrom (auf das zielt, unter anderem, auch Firdapse von CPRX ab )

Das was es schon gibt ( drug made by Jacobus (3,4-Dap) that treats the same disease ) , hat aber keine FDA Zulassung.

eben, das mittelchen von Jacobus steht unter dem sogenannten "compassionate use" richtlinie..

Jacobus ist nun angepisst

Ich denke wenn Firdapse von CPRX zugelassen wird, hat Jacobus nach langer Zeit ein Problem.. Daher versucht Jacobus, CPRX zu stoppen...

Jacobus will nun auch nen trial starten und so die formelle Zulassung zu erhalten, nöglichst vor CPRX

des weiteren, die Kanzlei Johnson & Weaver leitete eine Untersuchung, ob bestimmte leitende Angestellte und Direktoren von Katalysator Pharmaceutical Partners, Inc. (Nasdaq: CPRX) verletzt staatlichen oder bundesstaatlichen Gesetze.

die Meinen dass CPRX hätte durchblicken lassen sollen, dass es schon was für LEMS auf dem Markt gibt..

http://translate.google.com/

quasi ein krimi ausgebrochen lol

high risk, high reward..aber fang keine fallenden messer..

kann mir vorstellen dass es noch weiter abserbeln könnte, bis klarheit herscht was die Kanzlei geschichte angeht.

mal sehn wies sich entwickelt, hab immer noch runde 100%, evtl. verk. ich nochmal paar am montag, je nach dem halt.

sehe bei meinen anderen favoriten geringere risiken, RNN , CVM ,IDRA, DRRX

DRRX 6 Month Chart

[Blocked Image: http://ih.advfn.com/p.php?pid=staticchart&s=N%5EDRRX&t=26&showctype=1&width=300&height=192&p=4&cb=7]

IDRA 6 Month Chart

[Blocked Image: http://ih.advfn.com/p.php?pid=staticchart&s=N%5EIDRA&t=26&showctype=1&width=300&height=192&p=4&cb=7]

RNN 6 Month Chart

[Blocked Image: http://ih.advfn.com/p.php?pid=staticchart&s=A%5ERNN&t=26&showctype=1&width=300&height=192&p=4&cb=7]

kleinerengel hat am 21.10.2013 - 15:56 folgendes geschrieben:

Quote

21-10-2013 15:51 RESEARCH ALERT-Catalyst Pharmaceutical: Aegis Capital raises target price

Oct 21 (Reuters) - Catalyst Pharmaceutical Partners Inc:

* Aegis Capital raises target price to $5.50 from $4; rating buy

Display More

habe nun gerade keine mehr, warte ab..

alles in allem sind doch ca 9k usd für mich rausgesprungen.Aber auch nur weil ich auch über 3usd verkauft hab.

Catalyst Pharmaceuticals (CPRX), a small-cap biopharmaceutical company that produces novel orphan drugs, and is thought to be the next Acadia(ACAD) among many investors, experienced a strong sell off on Friday after an investigative report from The Street's senior columnist, Adam Feuerstein. The article bashed the company for attempting to profit off of sick people with their upcoming drug Firdapse, and almost portrayed Catalyst Pharmaceuticals as an evil company. Because nothing has fundamentally changed for the company, and the article was somewhat biased and only talked about one segment of Catalyst's pipeline, I believe now is the perfect time to open a speculative position in this potential blockbuster pharmaceutical company if you haven't already.

The Article

The article, "Catalyst Pharma: Orphan Drug Poseur, Profiteer" by Adam Feuerstein presents an in depth look at the current treatment available for patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS), and slams Catalyst for attempting to move into this space with their drug Firdapse, which has already been approved in Europe, and was recently awarded breakthrough therapy designation from the FDA in August of this year. Catalyst received the rights from Biomarin Pharmaceuticals (BMRN) to market Firdapse in the United States, and is currently finishing Biomarin's Phase III study with top-line results expected in 2014. Because of Firdapses success in Europe, there is a high likelihood that the FDA will approve the drug and Catalyst will commence sales by 2016.

DURECT Corporation : Pfizer Proceeding with REMOXY® Development

10/22/2013

http://www.4-traders.com/DUREC…OXY-Development-17384539/

kleinerengel hat am 02.10.2013 - 06:54 folgendes geschrieben:

Quote

Wie sieht es eigentlich mit OXBT aus...zzt kleines Volumen... wäre die auch noch was?

Oxygen Biotherapeutics Signs Agreement to Acquire Phase 3, FDA Fast Track Product

http://ih.advfn.com/p.php?pid=nmona&article=59688658

49.29%

CPRx

Catalyst Pharmaceutical Partners, Inc.’s share price has entered into oversold territory with an RSI value of 25.81. The Zacks Consensus Estimate on Catalyst Pharmaceutical Partners, Inc.’s earnings for the full year period has loss of 0.01 cents over the past two months to $-0.25 per share. Currently, Catalyst Pharmaceutical Partners, Inc. is a Zacks #1 Rank (“Strong Buy”), suggesting that now might be a good time to get in on after its recent drop.

LOL kanns nicht glauben, hab heut wieder 2k stk gekauft..

b00n hat am 21.09.2013 - 20:31 folgendes geschrieben:

Quote

b00n hat am 23.08.2013 - 21:24 folgendes geschrieben:

BELLUS Health Inc : Pharma Boardroom interview with Bellus CEO Roberto Bellini

.....

Bellus Health's primary pharmaceutical candidate, Kiacta, is in phase III clinical trials. What is this compound's latest development?

Kiacta is Bellus' most advanced and important product, which is currently in the last stage of testing, phase III. It is for a rare disease, AA amyloidosis, which affects the kidneys of 30,000 to 50,000 patients in United States, Europe and Japan. AA amyloidosis patients' kidney functions deteriorate quite rapidly from diagnosis and within 10 years, most are on dialysis or dead. Kiacta binds the amyloid inhibiting it from forming toxic fibrils and plaques that clog the kidneys. Bellus' phase II/III study demonstrated a 42 percent risk reduction in kidney damage for patients on Kiacta. The potential market size is approximately half a billion dollars per year in peak sales.

Bellus has agreements with the FDA and EMEA to run a confirmatory phase III study, which is currently on-going. If this study generates similar results to the first study, Kiacta will receive approval.

......

Bellus put a partnership in place with an American private equity group called Auven Therapeutics to finance the phase III confirmatory study of Kiacta. This group gave Bellus a $10 million upfront payment, and made a commitment of $50 million for the phase III study of Kiacta. After speaking to the FDA, the design for the Kiacta phase III study was done in-house and the actual execution is being done by a CRO. This overall strategy allowed Bellus Health to reduce its size to ten employees. The burn rate has been reduced considerably as well, from $2 million per month to less than $300,000 per month

.....

http://www.4-traders.com/BELLU…Roberto-Bellini-17282759/

https://www.google.com/finance…LU&ei=3eU9UtDTE9DCwAOBngE

Display More

endlich mal die 0.4 geknackt

BLU 6 Month Chart

[Blocked Image: http://ih.advfn.com/p.php?pid=staticchart&s=T%5EBLU&t=26&showctype=1&width=300&height=192&delay=1&p=4&cb=3]

Nedoli, nö hab keine..

Aurum

danke für die zusammenstellung, habe DNDN natürlich auf watch..

BLU

BELLUS Health Out-Licenses VIVIMIND, BLU8499 and Its Analogs

....

"VIVIMIND(TM) and BLU8499 are being divested to knowledgeable partners who can increase the potential of creating value for BELLUS Health's shareholders," said Roberto Bellini, Chief Executive Officer of BELLUS Health. "This transaction also allows us to focus entirely on the development of drugs for rare diseases, including KIACTA(TM) for AA amyloidosis, which is currently in a Phase 3 confirmatory study, and Shigamabs(TM), a clinical-stage product for the treatment of STEC-related Hemolytic Uremic Syndrome."

As part of the transactions, BELLUS Health will receive a cash consideration from FB Health, an equity stake in FB Health as well as royalties and a share of BLU8499 revenues from Alzheon.

VIVIMIND(TM) Transaction

As part of the transaction, BELLUS Health has licensed the worldwide rights to VIVIMIND(TM) to FB Health S.p.A. ("FB Health") for a cash consideration of more than $2 million representing a premium of four times VIVIMIND(TM) revenues generated in 2012. The consideration is to be paid over the next four years

......

mehr: http://online.wsj.com/article/PR-CO-20131023-904604.html